uPar fragment



uPar fragment

G1GG1R2RR2P3PP3C4CC4L5LL5P6PP6W7WW7N8NN8S9SS9A10AA10T11TT11V12VV12L13LL13Q14QQ14Q15QQ15T16TT16Y17YY17H18HH18A19AA19H20HH20R21RR21S22SS22D23DD23A24AA24L25LL25Q26QQ26L27LL27G28GG28L29LL29G30GG30K31KK31H32HH32N33NN33Y34YY34C35CC35R36RR36N37NN37P38PP38D39DD39N40NN40R41RR41R42RR42R43RR43P44PP44W45WW45C46CC46Y47YY47... and 140 more residue(s)...... and 140 more residue(s)

SMILES None
InChIKey None
Sequence GRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHN

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

uPar fragment

G1GG1R2RR2P3PP3C4CC4L5LL5P6PP6W7WW7N8NN8S9SS9A10AA10T11TT11V12VV12L13LL13Q14QQ14Q15QQ15T16TT16Y17YY17H18HH18A19AA19H20HH20R21RR21S22SS22D23DD23A24AA24L25LL25Q26QQ26L27LL27G28GG28L29LL29G30GG30K31KK31H32HH32N33NN33Y34YY34C35CC35R36RR36N37NN37P38PP38D39DD39N40NN40R41RR41R42RR42R43RR43P44PP44W45WW45C46CC46Y47YY47... and 140 more residue(s)...... and 140 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.